Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.78 |
| ▸ | P2RY2 | P41231 | 11/20 | 0.73 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.73 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.73 |
| ▸ | POLG | P54098 | 2/20 | 0.69 |
| ▸ | DUT | P33316 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Deoxycytidine Triphosphate SCHEMBL12595481 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL27673667 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL12729518 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL29725285 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL28008985 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL42135 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL29030090 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL18785037 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| Deoxycytidine Triphosphate SCHEMBL703664 | 1.00 | POLB (0.78) | POLBP2RY2P2RY4P2RY6POLG | |
| SCHEMBL28420890 | 0.99 | POLB (0.76) | POLBP2RY2P2RY4P2RY6POLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | claimed |
| CN-119677866-A | Substrate cleavage for nucleic acid synthesis | 特韦斯特生物科学公司 | 2025-03-21 | — | — | CN | claimed |
| EP-4504959-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | Twist Bioscience Corporation (US) | 2025-02-12 | — | — | EP | claimed |
| US-20240344057-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation | 2024-10-17 | — | — | US | claimed |
| WO-2023196499-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | Twist Bioscience Corporation (US) | 2023-10-12 | — | — | WO | claimed |
| EP-4229210-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation (US) | 2023-08-23 | — | — | EP | claimed |
| WO-2022086866-A1 | METHODS OF SYNTHESIZING OLIGONUCLEOTIDES USING TETHERED NUCLEOTIDES | Twist Bioscience Corporation (US) | 2022-04-28 | — | — | WO | claimed |
| US-20260132223-A1 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | ANSA BIOTECHNOLOGIES INC (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4731762-A2 | DE NOVO STEPWISE TEMPLATE-INDEPENDENT SYNTHESIS OF LONG POLYNUCLEOTIDES | Ansa Biotechnologies, Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20250369027-A1 | SUBSTRATE CLEAVAGE FOR NUCLEIC ACID SYNTHESIS | TWIST BIOSCIENCE CORP (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4594480-A2 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | Ansa Biotechnologies, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024073349-A9 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | ANSA BIOTECHNOLOGIES, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| CN-119677866-A | Substrate cleavage for nucleic acid synthesis | 特韦斯特生物科学公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20150090936-A1 | LARGE STOKES SHIFT DYES | Life Technologies Corporation | 2015-04-02 | — | — | US | disclosed |
| US-20110313129-A1 | LARGE STOKES SHIFT DYES | Life Technologies Corporation (US) | 2011-12-22 | — | — | US | disclosed |
| EP-2396318-A2 | LARGE STOKES SHIFT DYES | Life Technologies Corporation (US) | 2011-12-21 | — | — | EP | disclosed |
| US-20110085977-A1 | Use of UTP for the diagnosis of stenoses and other conditions of restricted blood flow | P2 SCIENCE APS (DK) | 2011-04-14 | — | — | US | disclosed |
| WO-2010093726-A2 | LARGE STOKES SHIFT DYES | Life Technologies Corporation (US) | 2010-08-19 | — | — | WO | disclosed |
| US-7132408-B2 | Composition and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. (US) | 2006-11-07 | — | — | US | disclosed |
| US-20040220133-A1 | Composition and method for inhibiting platelet aggregation | INSPIRE PHARMACEUTICALS, INC. | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150090936-A1 | LARGE STOKES SHIFT DYES | SLC7A5, SLC43A1, HCCS | POLB 4822/4885P2RY2 4248/4885P2RY4 3214/4885 |
| US-20040220133-A1 | Composition and method for inhibiting platelet aggregation | P2RY11, P2RY12, P2RY13 | POLB 1256/4885P2RY2 6/4885P2RY4 7/4885 |
| US-20110085977-A1 | Use of UTP for the diagnosis of stenoses and other conditions of restricted blood flow | NUDT1, UMPS, SLC35B2 | POLB 382/4885P2RY2 69/4885P2RY4 34/4885 |
| US-20110313129-A1 | LARGE STOKES SHIFT DYES | SLC7A5, SLC43A1, HCCS | POLB 4822/4885P2RY2 4248/4885P2RY4 3214/4885 |
| US-20260132223-A1 | CLEAVABLE LINKERS FOR THE TETHERING OF POLYMERASES TO NUCLEOTIDES | POLN, PCNA, POLB | POLB 3/4885P2RY2 3845/4885P2RY4 3826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.